Details for Patent: 9,309,229

Which drugs does patent 9,309,229 protect, and when does it expire?

Patent 9,309,229 protects ZYKADIA and is included in two NDAs.

This patent has sixty-six patent family members in thirty-four countries.

Summary for Patent: 9,309,229

Title:	Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propan- e-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Abstract:	The present invention describes specific crystalline forms of 5-chloro-N-(2-isopropoxy-5-methyl-4-(piperidin-4-ylphenyl)-N-2-(isopropyl- sulfonyl)phenyl)-2,4-diamine. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.
Inventor(s):	Feng; Lili (Pine Brook, NJ), Gong; Baoqing (Morris Plains, NJ), Karpinski; Piotr H. (Lincoln Park, NJ), Waykole; Liladhar Murlidhar (Succasunna, NJ)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/993,217
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 9,309,229

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No			Y	Y
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 9,309,229

PCT Information
PCT Filed	December 15, 2011	PCT Application Number:	PCT/US2011/065030
PCT Publication Date:	June 21, 2012	PCT Publication Number:	WO2012/082972

International Family Members for US Patent 9,309,229

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	084309
Argentina	122395
Australia	2011343775
Brazil	112013015000
Canada	2821102